Optimi Health Corp. (OPTH)
| Market Cap | 25.22M +41.6% |
| Revenue (ttm) | 123,703 -68.0% |
| Net Income | -4.86M |
| EPS | -1.39 |
| Shares Out | 5.73M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 39,054 |
| Open | 4.550 |
| Previous Close | 4.500 |
| Day's Range | 4.360 - 4.640 |
| 52-Week Range | 4.000 - 8.838 |
| Beta | 1.59 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About OPTH
Optimi Health Corp. operates as a pharmaceutical and nutraceutical drug manufacturing company in Canada. The company manufactures controlled substances including finished MDMA and psilocybin drug products, supplying them directly to authorized clinics, pharmacies, clinical trials, and partners. The company produces and supplies MDMA, natural psilocybin, psilocin, other psychedelic substances, and functional mushrooms derived from botanical sources for health and wellness markets. The company also engages in farming, processing, and distribution... [Read more]
Financial Performance
In fiscal year 2025, Optimi Health's revenue was 426,301, an increase of 9.35% compared to the previous year's 389,850. Losses were -3.71 million, -38.50% less than in 2024.
Financial numbers in CAD Financial StatementsNews
Optimi Health Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Currently commercial with psilocybin and MDMA products in Australia and Canada, the company is expanding globally as regulatory frameworks evolve. With a regulatory-first approach and strong financial backing, it is positioned as a leader in natural psychedelic manufacturing.
Optimi Health to initiate Phase 2 trial of psilocybin-assisted therapy for MDD
Optimi Health (OPTH) announces plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for individuals with major depressive disorder. The trial is planned to be in...
Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
Health Canada-authorized trial to evaluate a single supervised dose of natural psilocybin, with dosing expected to be completed by the end of 2027
Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: OPTH) (CSE: OPTI) (“Optimi” or the “Company”), a commercial-stage pharmaceutical manufacturer of regulated ...
Optimi Health Registration statement: Registration filing
Optimi Health filed a registration statement on August 17, 2026, providing details about a securities offering with the SEC.
Optimi Health files to sell 21.94M common shares for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 21.94M common shares. The company is not selling any shares under…
Optimi Health files to sell 21.94M common shares for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 21.94M common shares. The company is not selling any shares under…
Optimi Health establishes discretionary equity facility
Optimi Health (OPTH) announced that it has entered into a common shares purchase agreement with Seven Knots, establishing an equity line of credit under which the company has the right,…
Optimi Health Registration statement: Q3 2026
Optimi Health filed a registration statement on August 14, 2026, providing details about a securities offering with the SEC.
Optimi Health Registration statement: Q3 2026
Optimi Health filed a registration statement on August 14, 2026, providing details about a securities offering with the SEC.
Optimi Health Establishes Discretionary Equity Facility
VANCOUVER, British Columbia, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (the “Company” or “Optimi”), a commercial-stage pharmaceutical manufacturer of ...
Optimi Health Slides: Investor presentation
Optimi Health has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Optimi Health completes psilocybin export to Australia
Optimi Health (OPTH) announced the completion of its latest export of 5mg psilocybin finished drug product to Australia, marking its third commercial shipment since the September 2025 launch of its…
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
Optimi's 5mg psilocybin capsules are prescribed in Australia for treatment-resistant depression. The export marks Optimi's third commercial shipment since launching the 5mg psilocybin capsules in Sept...
Optimi launches standardized microdose psilocybin products for clinical research
Optimi Health (OPTH) announced it has completed production of two microdose psilocybin finished drug products, formulated at 1 mg and 2 mg dosages. The products are available to qualified, authorized…
Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies New microdose formats extend Optimi's psilocyb...
Psychedelic: Optimi Health completes psilocybin export to the UK
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a psilocybin export, an analyst initiation and a CFO appointment. OPTIMI COMPLETES…
Optimi Health completes first export of naturally derived psilocybin to the UK
Optimi Health (OPTH) announced the completion of its first export of naturally derived psilocybin to the United Kingdom in support of a planned Phase 2 clinical trial. The shipment comprises…
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the United Kingdom and was completed under export authorization fro...
Optimi Health commences finished ibogaine drug product development
Optimi Health (OPTH) provided an update on its recently announced “Ibogaine Initiative,” stating that Optimi has secured naturally derived ibogaine from two sources, in both hydrochloride and freebase...
Optimi Health secures ibogaine supply
Optimi Health (OPTH) provided an update on its recently announced Ibogaine initiative. Optimi has secured naturally derived ibogaine from two sources, in both hydrochloride and freebase form. Developm...
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
Recent US executive order named ibogaine compounds among the psychedelic therapies prioritized for accelerated FDA review and expanded patient access Ibogaine is under investigation to treat PTSD, opi...
Optimi Health completes commercial production of psilocybin capsules
Optimi Health (OPTH) announced the completion of a good manufacturing practice production run of its 5mg psilocybin finished drug product. The capsules use the same formulation currently prescribed in...
Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
Optimi's 5mg psilocybin capsules are prescribed commercially for treatment-resistant depression in Australia, with additional product from the run earmarked for planned clinical trials in the United S...
Optimi Health Registration statement: Q2 2026
Optimi Health filed a registration statement on May 31, 2026, providing details about a securities offering with the SEC.